The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Acetamoren
MK-777 is a recently developed research chemical that claims to improve on MK-677. Before discussing those claims, the evidence base for them must be clearly established: it is essentially zero published independent research.
Ibutamoren (MK-677) was developed by Merck in the 1990s as an oral, non-peptide ghrelin receptor agonist for potential use in growth hormone deficiency, muscle wasting, and osteoporosis. It has been through Phase 1 and Phase 2 clinical trials, has published human pharmacokinetic data, and has accumulated over a decade of community use experience with a reasonably well-characterized safety and effects profile. The pbmk677v4 chapter covers this in detail.
MK-777 (Acetamoren; CAS 950841-87-9) appears to have entered commercial availability around 2024 via research chemical vendors. Vendors describe it as a fourth-generation GHS-R1a agonist, structurally based on MK-677 with chemical modifications including a fluorine substituent and thioether backbone modification. The claimed properties — 92% higher GHS-R1a binding affinity, Ki = 0.8 nM, 8-10h half-life, 18-22h IGF-1 elevation, SSTR2/5 allosteric modulation — are not sourced to published peer-reviewed studies in vendor product descriptions. A vendor (Kimera Chems) explicitly notes: 'As a relatively novel compound within the non-peptide GHS class, MK-777 has limited primary peer-reviewed literature coverage relative to established class members.' This is an understatement; the published literature appears to be essentially nonexistent for MK-777 specifically.
THE CENTRAL TENSION
MK-777 presents the most challenging evidence evaluation problem of any compound in this chapter set: its claimed pharmacological properties are presented with numerical precision (Ki = 0.8 nM; 92% greater binding affinity; 8-10h half-life; 18-22h IGF-1 elevation) but the source of these numbers is not independent peer-reviewed research — it is vendor characterization. The GHS-R1a mechanism it claims is well-established via MK-677. The specific improvements claimed for MK-777 over MK-677 are not. A community that has already established that MK-677 works well for GH secretagogue applications now faces a choice: use the well-characterized compound with clinical data, or use the analog with vendor-claimed improvements and no published validation. The appropriate response is to treat MK-777's class mechanism (GHS-R1a agonism) as Grade C/B via MK-677 extrapolation, and MK-777's specific claimed enhancements as Grade E (vendor claim; unvalidated by independent research).
ACTIVE MALIGNANCY — CAUTION (GH/IGF-1 ELEVATION)
IGF-1 is mitogenic. Elevated IGF-1 is associated with increased cancer risk in epidemiological studies. Active malignancy is a caution for all GH secretagogues. This applies to MK-777 via the class mechanism. If the SSTR2/5 modulation claim is accurate and MK-777 produces larger GH pulses than MK-677, the IGF-1 elevation may be greater, increasing this concern relative to MK-677.
Appetite stimulation: GHS-R1a hypothalamic activation; can be significant; similar to GHRP-6 but less acute; relevant for users in caloric restriction. Water retention: GH/IGF-1 elevation causes sodium/water retention; peripheral edema; particularly pronounced in the first 2-4 weeks. Insulin resistance: GH elevation has insulin-antagonizing effects; fasting glucose and HbA1c monitoring recommended on extended protocols. Sleep deepening: GHRH-mediated slow-wave sleep enhancement; generally considered beneficial but can cause vivid dreams. Mild transient carpal tunnel symptoms: from water retention and IGF-1 effects on soft tissues.
MK-777's core mechanism — GHS-R1a activation — is the same as MK-677 and is well-established. This section uses MK-677 evidence to establish the pharmacological framework that MK-777 claims to operate within.
GHS-R1a (ghrelin receptor) is a Gq-coupled GPCR on pituitary somatotrophs and hypothalamic neurons. Activation by MK-677 (and by extension MK-777, if claims are accurate) triggers: GH exocytosis from pituitary somatotrophs; GH-stimulated IGF-1 production from the liver; appetite stimulation (hypothalamic NPY/AgRP neurons); enhanced slow-wave sleep via GHRH co-activation. These are the same mechanisms that make GHRP-6 and ipamorelin work, from the same receptor. Non-peptide GHS-R1a agonists (MK-677 class) differ from peptide GHRPs primarily in: oral bioavailability (peptides are destroyed orally; small molecules are not); half-life (MK-677 has a 24h IGF-1 elevation from a single dose vs hours for peptide GHRPs); and the consequently sustained (rather than pulsatile) GH signal they produce.
Vendors describe MK-777 as having: (1) higher GHS-R1a binding affinity (Ki = 0.8 nM vs MK-677's Ki reported at various 1-4 nM in different assay systems); (2) a fluorinated thioether backbone that resists first-pass hepatic metabolism, extending half-life to 8-10h vs MK-677's ~6h; (3) SSTR2 and SSTR5 allosteric modulation that additionally reduces somatostatin suppression of GH, potentially amplifying the GH pulse beyond GHS-R1a agonism alone. If accurate, these modifications would produce a compound with: greater GH stimulation per mg; longer duration of action; and potentially a cleaner metabolic profile (fluorine substitution often improves metabolic stability in medicinal chemistry). The key qualifier: these properties have not been independently confirmed in published research.
The claim that MK-777 allosterically modulates somatostatin receptors SSTR2 and SSTR5 is the most pharmacologically significant distinction from MK-677 if true. Somatostatin acts as the brake on GH release — it inhibits both GHRH-stimulated and GHS-R1a-stimulated GH secretion. Drugs that combine GHS-R1a agonism with somatostatin receptor inhibition would theoretically produce larger GH pulses than either mechanism alone — this is the same logic behind using CJC-1295 (GHRH) with ipamorelin (GHRP) in the GH Stack chapter. If MK-777 simultaneously agonizes GHS-R1a and antagonizes SSTR2/5, it would be a self-contained GHRH-analog-equivalent stack in a single molecule. This claim has no published supporting evidence as of mid-2026.
Feature
MK-677 (Ibutamoren)
MK-777 (Acetamoren)
Evidence Status
Structure
C₂₇H₃₆N₄O₅S; MW 528.67; spiroindoline-piperidine core
C₂₈H₃₅FN₄O₅S; MW 558.68; fluorinated thioether modification
Confirmed by mass spec
GHS-R1a binding
Ki ~1-4 nM (varies by assay); established via published studies
Ki = 0.8 nM; 92% greater affinity claimed
MK-677: published; MK-777: vendor claim only
Half-life
~6h; IGF-1 elevation 24h from single dose (published PK)
8-10h claimed; 18-22h IGF-1 claimed
MK-677: published human PK; MK-777: vendor claim
SSTR modulation
No SSTR activity described
Claims SSTR2/5 allosteric modulation
MK-677: confirmed absence; MK-777: claim unverified
First-pass metabolism
Undergoes significant first-pass; oral bioavailability ~60-70%
Fluorinated backbone claimed to resist first-pass
MK-677: published; MK-777: structural inference
Human clinical trials
Phase 1 (safety); Phase 2 (GH deficiency, frailty, Alzheimer's study)
Zero human clinical trials
Clear distinction
Human PK data
Published (Patchett et al. 1999; multiple subsequent)
None published
Critical gap
IGF-1 elevation in humans
+35-89% in published studies; well-characterized
Claimed 18-22h duration; magnitude not independently studied
MK-677: measured; MK-777: claimed
S2 — banned
S2 — banned (same class)
Both banned in sport
Community experience
10+ years; established dosing (12.5-25mg oral); appetite/sleep/water retention profile well-described
2024 onwards; emerging community reports; limited experience base
MK-677: extensive; MK-777: very limited
Because MK-777 claims the same fundamental mechanism as MK-677, MK-677’s established clinical data provides the pharmacological framework. This framework applies to the mechanism; not to MK-777’s specific claimed enhancements.
MK-677 (ibutamoren) is the most extensively studied oral non-peptide GHS-R1a agonist. Key published evidence applicable to the class mechanism: Nass et al. (2008, JCEM): elderly subjects; MK-677 12mg or 25mg/day for 2 years; increased GH pulsatility, elevated IGF-1, improved sleep quality and slow-wave sleep; increased lean body mass; increased bone mineral density. Svensson et al. (1998): healthy elderly men; MK-677; GH and IGF-1 elevation; body composition improvement. Murphy et al. (1998, JCEM): hip fracture patients; MK-677; increased GH and IGF-1; enhanced muscle mass preservation. Copinschi et al. (1997): sleep-enhancing effects via GHRH and slow-wave sleep promotion. These studies establish the GHS-R1a agonism class mechanism at work. They do NOT validate MK-777's specific claims about enhanced potency, longer half-life, or SSTR modulation.
Community MK-777 protocols extrapolate from MK-677 experience. Given vendor claims of higher potency (Ki = 0.8 nM vs ~1-4 nM) and longer half-life, community protocols tend toward lower doses than MK-677. Limitless: 12.5 mg capsules. Community reports: 12.5-25mg/day oral; before bed (sleep enhancement; appetite management; consistent with MK-677 timing rationale). If the claimed SSTR2/5 modulation is real, dosing might differ from MK-677 in ways the community has not yet established. Effects onset consistent with class: IGF-1 elevation detectable within 1-2 weeks; sleep quality improvement often reported in first week; appetite increase in first 2-4 weeks. Cycle length: community uses 4-12 weeks; some continuous use (mirroring MK-677 long-term trial protocols); IGF-1 monitoring recommended.
Ki values from receptor binding assays characterize in vitro receptor affinity. Higher affinity does not automatically translate to better clinical outcomes — receptor affinity is one of many factors determining in vivo potency including oral bioavailability, plasma protein binding, CNS penetration, metabolite activity, and receptor desensitization dynamics. The Ki = 0.8 nM claim for MK-777 has not been independently replicated in a published study; it derives from vendor characterization. MK-677's Ki values have been published and replicated across multiple laboratory groups.
If the SSTR2/5 allosteric modulation claim is accurate, MK-777 has additional pharmacological activity that MK-677 does not have. A compound with a different pharmacological profile has a potentially different safety profile. The class-wide GH secretagogue safety data (from MK-677 studies) applies to the GHS-R1a mechanism; it does not characterize the safety of simultaneous SSTR modulation, which has not been studied in this compound.
Numerical precision in vendor claims (92% higher binding affinity; Ki = 0.8 nM; 18-22h IGF-1 elevation) does not by itself constitute scientific validation. These numbers should come from published, peer-reviewed, independently conducted pharmacological studies. Without published source papers, numerical precision is marketing precision, not scientific validation. The appropriate epistemic position is to note these claims while acknowledging their unvalidated status.
Nass R, et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 149(9):601-11. [MK-677 2-year study; GH/IGF-1 elevation; lean mass; sleep; adverse effects; most relevant MK-677 long-term human data.]
Patchett AA, et al. (1999). Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci. 92(15):7001-5. [Original MK-677 design and pharmacology paper; structure-activity; Ki; oral bioavailability. The foundational GHS class non-peptide characterization.]
Liu H, et al. (2021). Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. Nat Commun. 12:5564. [Cryo-EM structure of GHS-R1a bound to ibutamoren; binding mode; GPCR activation mechanism; provides structural context for MK-677 class compounds including MK-777.]
MK-777/Acetamoren CAS 950841-87-9. Vendor product specifications (Umbrella Labs, Limitless Biotech, Kimera Chems). [Vendor-derived characterization: Ki = 0.8 nM; C₂₈H₃₅FN₄O₅S; MW 558.68; SSTR2/5 modulation claim; no independent peer-reviewed publication. Note: vendor source only.]
MK-777 is a real compound with a real chemical identity and a plausible mechanism. Whether its claimed advantages over MK-677 are real has not been independently validated.
The compound's story: research chemical labs designed a structural analog of MK-677 with modifications claimed to improve binding affinity, half-life, and metabolic stability, and possibly add SSTR modulatory activity. The chemical modifications (fluorinated backbone, thioether) are consistent with standard medicinal chemistry approaches for improving metabolic stability and receptor affinity. The claimed pharmacological properties are numerically specific and plausible in direction. None of them have been confirmed in published independent research as of mid-2026. The community using MK-777 is essentially running a self-experiment with a 2024-era research chemical whose core class mechanism is well-established via MK-677 but whose specific claimed improvements are unverified. This is not a safety condemnation — the compound may well perform as claimed. It is an evidence statement.
— End of MK-777 (Acetamoren) —
THE PEPTIDE BIBLE | MK-777 (Acetamoren) | For Research & Educational Purposes Only
MK-777 (Acetamoren): CAS 950841-87-9; C₂₈H₃₅FN₄O₅S; MW 558.68 g/mol. Non-peptide small-molecule GHS-R1a (ghrelin receptor) agonist. Structural analog of ibutamoren (MK-677; CAS 159634-47-6; C₂₇H₃₆N₄O₅S; MW 528.67). Fourth-generation GHS compound. First commercially available ~2024. Limitless: 12.5mg capsules, 60/bottle. WADA S2 — banned. NOT FDA-approved. CLAIMED ENHANCEMENTS vs MK-677 (all unvalidated by independent published research): Ki = 0.8 nM (92% higher GHS-R1a binding affinity); half-life 8-10h (vs MK-677 ~6h); IGF-1 elevation 18-22h (vs MK-677 ~24h similar duration); SSTR2/5 allosteric modulation (reduces somatostatin brake simultaneously with GHS-R1a agonism — potentially larger GH pulses); fluorinated thioether backbone resists first-pass metabolism. EVIDENCE STATUS: Zero independent peer-reviewed publications for MK-777 as of mid-2026. All specific property claims derive from vendor characterization. CLASS MECHANISM (via MK-677 data; Grade C/B): GHS-R1a Gq activation → pituitary GH release; hepatic IGF-1 elevation; appetite stimulation (arcuate nucleus NPY/AgRP); slow-wave sleep enhancement (GHRH co-pathway); body composition (lean mass, bone density) from MK-677 trials. COMMUNITY PROTOCOL (extrapolated from MK-677): 12.5-25mg oral once daily before bed; 4-12 week cycles; IGF-1 monitoring at baseline and 6-8 weeks. SAFETY (class-based): appetite stimulation; water retention; insulin resistance; IGF-1 mitogenic (active malignancy caution); sleep changes; carpal tunnel (water retention, IGF-1). MK-777-specific: fluorine metabolite profile unknown; SSTR modulation safety (if real) uncharacterized. THE COMPARISON: MK-677 has Phase 1/2 human trials, published PK, decade community experience. MK-777 has none of this. Choose MK-677 for validated GHS effects. Use MK-777 with explicit understanding that claimed enhancements are unverified.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.